New data release at LINC 2019 reinforces safety profile of low-dose Stellarex DCB

Sean Lyden (Cleveland, USA) and Fabrizio Fanelli (Rome, Italy) discuss the safety and future of drug-coated balloons (DCB) in light of the latest pooled analysis of patient-level data of over 2,300 patients treated with Philips’ Stellarex DCB in above-the-knee studies.

The independent, third party pooled analysis, presented by Lyden at LINC 2019, demonstrated low mortality rates through three years after the treatment with no device-related deaths.

This video is sponsored by Philips.

Lyden, Sean

Sean Lyden, MD, is the Chairman of the Robert and Suzanne Tomsich Department of Vascular Surgery at Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute.

Add comment

    Subscribe to receive the very best in medical videos

    /* ]]> */